



## Research 2.0 Updates Coverage of Viral Genetics with Research Report Focused on VG Energy

*SOURCE: Viral Genetics, Inc.*

### ***Research 2.0 Updates Coverage of Viral Genetics with Research Report Focused on VG Energy***

#### *Business Wire*

SAN MARINO, Calif., June 15, 2011 /PRNewswire/ — Viral Genetics, Inc., (Pinksheets:VRAL.pk – News) is pleased to announce that Boston-based Research 2.0 today released an 8-page report focused on the Company's majority-owned subsidiary, VG Energy, Inc. The report is available on the company's website at [www.viralgenetics.com/investors/research20\\_June2011.php](http://www.viralgenetics.com/investors/research20_June2011.php) and is also distributed over the internet and through institutional platforms including FactSet, CapitalIQ, and TheMarkets.com.

Research 2.0 is pioneering a new "open professional" model of investment research which gives companies a direct path to quality independent institutional research coverage via an annual retainer and making that research broadly available to all potential investors on the Internet and in open social and professional online networks.

"As with any coverage like this we will let the report and analysts speak for themselves, but we are very pleased to see the exciting new developments at VG Energy get professionally analyzed, described and evaluated for all of our stakeholders," said Viral Genetics and VG Energy CEO, Haig Keledjian.

#### **About Viral Genetics, Inc.**

San Marino, California-based Viral Genetics discovers drug therapies from two platform technologies based on over 60 patents: Metabolic Disruption (MDT) and Targeted Peptides (TPT). Founded in 1994, the biotech company is researching treatments for HIV/AIDS, Lyme Disease, Strep, Staph and drug resistant cancer. A majority-owned subsidiary, VG Energy ([www.vgenenergy.net](http://www.vgenenergy.net)), is dedicated to exploring biofuel and agricultural applications for the MDT platform. For more information, visit [www.viralgenetics.com](http://www.viralgenetics.com).

**SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:** This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports, including statements about its VG Energy, Inc. subsidiary. None of Viral Genetics' drug compounds are approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world, nor are any non-pharmaceutical products of VG Energy, Inc. commercialized. While Viral Genetics believes that the forward-looking statements and underlying assumptions reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of any of its drug therapies in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of those drug compounds in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, the successful outcome of such studies or tests, or the successful commercialization of VG Energy, Inc.'s non-pharmaceutical products. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.



**Contact:**

Viral Genetics, Inc.

Haig Keledjian, 626-334-5310

